CoChat

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy

Open access
Yilmaz, Ahmet, Cui, Hanwei, Caligiuri, Michael A., Yu, Jianhua · 2020 · Journal of Hematology & Oncology

The DOI matches its Crossref record; 229 of the 230 references it cites were found in a registry or an index.

Abstract

Natural killer (NK) cells are a critical component of the innate immune system. Chimeric antigen receptors (CARs) re-direct NK cells toward tumor cells carrying corresponding antigens, creating major opportunities in the fight against cancer. CAR NK cells have the potential for use as universal CAR cells without the need for human leukocyte antigen matching or prior exposure to tumor-associated antigens. Exciting data from recent clinical trials have renewed interest in the field of cancer immunotherapy due to the potential of CAR NK cells in the production of “off-the-shelf” anti-cancer immunotherapeutic products. Here, we provide an up-to-date comprehensive overview of the recent advancements in key areas of CAR NK cell research and identify under-investigated research areas. We summarize improvements in CAR design and structure, advantages and disadvantages of using CAR NK cells as an alternative to CAR T cell therapy, and list sources to obtain NK cells. In addition, we provide a list of tumor-associated antigens targeted by CAR NK cells and detail challenges in expanding and transducing NK cells for CAR production. We additionally discuss barriers to effective treatment and suggest solutions to improve CAR NK cell function, proliferation, persistence, therapeutic effectiveness, and safety in solid and liquid tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-020-00998-9

Cites

229 of 229 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Representative steps in CAR NK cell manufacturing for immunotherapy, RCL/RCR replication competent lentivirus/retrovirus measured by qPCR for detection of DNA encoding a viral envelope
Fig. 1 Representative steps in CAR NK cell manufacturing for immunotherapy, RCL/RCR replication competent lentivirus/retrovirus measured by qPCR for detection of DNA encoding a viral envelopeCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 229 references

Research works printed but not linked: 3

  1. O’Leary M. Biologic License Application Clinical Review Memorandum. Biologics license application 2017:12.
  2. Kurlander R. Approval of CD19-directed CAR T cells: FDA licensure of new cell-based gene therapy products with a challenging safety profile. FDA clinical review memorandum 2017:9.
  3. Alsamah W, Romia Y. Modification of natural killer cells to target tumors. Int J Pharm Clin Res. 2014;6(1):97–100.

Cited by

See all 183

Metadata

Authors
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J.
Affiliations
  • The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
  • City Of Hope National Medical Center (US)
Corresponding author
Yu, Jianhua
Venue
Journal of Hematology & Oncology
Published
2020-12
Volume
13
Issue
1
Pages
168-168
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3112748109
Cited by
171
References
230
Citations by year
2026: 8 · 2025: 18 · 2024: 30 · 2023: 42 · 2022: 38 · 2021: 35
FWCI
3.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Hematology & Oncology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (AI129582, CA247550, NS106170, CA223400, CA210087, CA068458, CA163205)
Topics
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
  • Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
chimeric antigen receptor, CAR-NK cells, natural killer cells, cancer immunotherapy, off-the-shelf cell therapy, automotive design, tumor-associated antigens, NK cell persistence, solid tumors, liquid tumors
MeSH terms
Receptors, Chimeric Antigen, Animals, Genetic Engineering, Humans, Killer Cells, Natural, Neoplasms, Transduction, Genetic, Immunotherapy, Adoptive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. https://app.cochat.ai/papers/10.1186/s13045-020-00998-9
The paper
Yilmaz, A., Cui, H., Caligiuri, M. A., & Yu, J. (2020). Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-020-00998-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.